You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

Article Text

Article menu

This article has a correction. Please see:

Download PDFPDF

Correction
Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
  1. Asim Amin1,a,
  2. Elizabeth R. Plimack2,
  3. Marc S. Ernstoff3,
  4. Lionel D. Lewis4,
  5. Todd M. Bauer5,
  6. David F. McDermott6,
  7. Michael Carducci7,
  8. Christian Kollmannsberger8,
  9. Brian I. Rini9,
  10. Daniel Y. C. Heng10,
  11. Jennifer Knox11,
  12. Martin H. Voss12,
  13. Jennifer Spratlin13,
  14. Elmer Berghorn14,
  15. Lingfeng Yang14 and
  16. Hans J. Hammers15
  1. Aff1 0000 0004 0387 0597grid.427669.8Immunotherapy program, Levine Cancer InstituteCarolinas HealthCare System 1024 Morehead Medical Drive 28204 Charlotte NC USA
  2. Aff2 0000 0004 0456 6466grid.412530.1Division of Genitourinary Medical Oncology, Department of Hematology/OncologyFox Chase Cancer Center 19111 Philadelphia PA USA
  3. Aff3 0000 0001 2181 8635grid.240614.5Division of Oncology, Department of MedicineRoswell Park Cancer Institute Elm and Carlton Streets 14203 Buffalo NY USA
  4. Aff4 0000 0004 0440 749Xgrid.413480.aDepartment of Medicine at The Geisel School of Medicine and The Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center 03756 Lebanon NH USA
  5. Aff5 0000 0004 0459 5478grid.419513.bSarah Cannon Research Institute/Tennessee Oncology, PLLC 37203 Nashville TN USA
  6. Aff6 0000 0004 5902 1762grid.477947.eDepartment of Medicine, Beth Israel Deaconess Medical CenterDana-Farber/Harvard Cancer Center 02215 Boston MA USA
  7. Aff7 0000 0000 8617 4175grid.469474.cDepartment of OncologyJohns Hopkins Sidney Kimmel Comprehensive Cancer Center 21287 Baltimore MD USA
  8. Aff8 0000 0001 0702 3000grid.248762.dDivision of Medical OncologyBritish Columbia Cancer Agency V5Z 4E6 Vancouver BC Canada
  9. Aff9 0000 0001 0675 4725grid.239578.2Lerner College of Medicine, Department of Hematology and OncologyCleveland Clinic Taussig Cancer Institute 44195 Cleveland OH USA
  10. Aff10 0000 0004 1936 7697grid.22072.35Department of Oncology, Tom Baker Cancer CenterUniversity of Calgary T2N 4N2 Calgary AB Canada
  11. Aff11 0000 0001 2150 066Xgrid.415224.4Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre M5G 1Z5 Toronto ON Canada
  12. Aff12 0000 0001 2171 9952grid.51462.34Department of MedicineMemorial Sloan Kettering Cancer Center 10065 New York NY USA
  13. Aff13 grid.17089.37Department of Oncology, Cross Cancer InstituteUniversity of Alberta T6G 1Z2 Edmonton AB Canada
  14. Aff14 grid.419971.3Oncology - Global Clinical ResearchBristol-Myers Squibb 08541 Princeton NJ USA
  15. Aff15 0000 0000 9482 7121grid.267313.2Department of Internal MedicineUT Southwestern – Kidney Cancer Program 75390 Dallas TX USA
  1. ↵a Asim.Amin{at}carolinashealthcare.org

Abstract

.

The original article can be found online at 10.1186/s40425-018-0420-0

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

View Full Text

http://dx.doi.org/10.1186/s40425-019-0559-3

Statistics from Altmetric.com

    The original article can be found online at 10.1186/s40425-018-0420-0

    Correction to: Journal for ImmunoTherapy of Cancer (2018) 6:109

    https://doi.org/10.1186/s40425-018-0420-0

    Following publication of the original article [1], the author reported a mistake related to a percentage. In page 5 the sentence “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (0.3%) had progressive disease, and in three patients (9.1%), response was undeterminable.” should be replaced with “Two (6.1%) patients achieved a complete response, 16 (48.5%) achieved a partial response, 11 (33.3%) had stable disease, one (3.0%) had progressive disease, and in three patients (9.1%), response was undeterminable.” (3.0% instead of 0.3%).

    The publisher apologizes for any inconvenience caused by this error.

    Reference

    1. 1.↵
      1. Amin A, et al
      . Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study. J Immunother Cancer. 2018;6:109doi:10.1186/s40425-018-0420-0pmcid:6196426
      OpenUrlAbstract/FREE Full Text
    View Abstract

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Copyright information:

    © The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.